123 0

Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer

Title
Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer
Author
공구
Keywords
GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR; H2A UBIQUITYLATION; DOWN-REGULATION; HER2 AMPLICON; STEM-CELLS; TRASTUZUMAB; RESISTANCE; EXPRESSION; SURVIVAL
Issue Date
2018-09
Publisher
OXFORD UNIV PRESS INC
Citation
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, v. 111, no. 6, page. 609-619, Article no. djy151
Abstract
Background: Resistance to HER2-targeted therapy with trastuzumab still remains a major challenge in HER2-amplified tumors. Here we investigated the potential role of MEL-18, a polycomb group gene, as a novel prognostic marker for trastuzumab resistance in HER2-positive (HER2+) breast cancer.Methods: The genetic alteration of MEL-18 and its clinical relevance were examined in multiple breast cancer cohorts including METABRIC (n=1,980), TCGA (n=825), and our clinical specimens (n=213, trastuzumab-treated HER2+ cases). MEL-18 amplification was validated by fluorescence in situ hybridization (FISH) analysis. The MEL-18 effect on trastuzumab response was confirmed by in vitro cell viability assays and an in vivo xenograft experiment (n=7 per group). Gene expression microarray and receptor tyrosine kinase array were performed to identify the trastuzumab resistance mechanism by MEL-18 loss. All statistical tests were two-sided.Results: MEL-18 was exclusively amplified in approximately 30-50% of HER2+ breast tumors and was associated with a favorable clinical outcome (disease-free survival: P = .02 in HER2+ cases, METABRIC; P = .04 in patients receiving trastuzumab). In MEL-18-amplified HER2+ breast cancer, MEL-18 depletion induced trastuzumab resistance by increasing ADAM sheddase-mediated ErbB ligand production and receptor heterodimerization. MEL-18 epigenetically silenced ADAM10/17 expression in cooperation with polycomb-repressive complex (PRC) 1 and PRC2. Combination treatment with an ADAM10/17 inhibitor and trastuzumab could overcome MEL-18 loss-mediated trastuzumab resistance in vivo (BT474/shMEL-18 xenograft: trastuzumab, mean [SD] tumor volume = 406.1 [50.1] mm(3), vs trastuzumab + GW280264 30mg/kg, mean [SD] tumor volume = 68.4 [15.6] mm(3), P < .001). Consistently, trastuzumab-treated patients harboring concomitant MEL-18 amplification and low ADAM17 expression showed prolonged relapse-free survival (P = .02 in our cohort, n=213).Conclusion: MEL-18 serves to prevent ligand-dependent ErbB heterodimerization and trastuzumab resistance, suggesting MEL-18 amplification as a novel biomarker for HER2+ breast cancer.
URI
https://academic.oup.com/jnci/article-abstract/111/6/609/5103386?redirectedFrom=fulltexthttps://repository.hanyang.ac.kr/handle/20.500.11754/119915
ISSN
0027-8874; 1460-2105
DOI
10.1093/jnci/djy151
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE